home / stock / gern / gern articles
The FDA’s Oncologic Drugs Advisory Committee will meet virtually on March 14, 2024, to review Geron Corporation’s (...
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported quarterly losse...
Guarav Aggarwal, Director at Geron (NASDAQ:GERN), reported a large acquisition of company stock options on November 28, according to a new SEC fili...
Faye Feller, EVP at Geron (NASDAQ:GERN), reported a large acquisition of company stock options on September 22, according to a new SEC filing. What...
Andrew J Grethlein, EVP at Geron (NASDAQ:GERN), reported a large acquisition of company stock options on September 22, according to a new SEC filin...
Olivia K. Bloom, EVP at Geron (NASDAQ:GERN), reported a large acquisition of company stock options on September 22, according to a new SEC filing. ...
Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a price target of $4. Recently, the FDA a...
News, Short Squeeze, Breakout and More Instantly...